Clinical oncology最新文献_第6页

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/S0936-6555(25)00035-4

引用次数: 0

Impact of anticoagulants on efficacy outcomes after initiation of Darolutamide in non- metastatic castrate resistant prostate cancer (nmCRPC) from the real world UK multi-centre RECORD study

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.10.026

A. Stavropoulos , A. Bahl , P. White , L. Ashurst , M. Randhawa , A. Challapalli

引用次数: 0

Efficacy and safety of neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab in patients with HER2-positive early breast cancer - A retrospective study

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103717

L. Koudsi, C. Hockaday, N. Levitt, M. Tuthill, R. Roux, S. Lord, J. Chiramel

引用次数: 0

Neoadjuvant chemotherapy for early breast cancer in young patients: real-world outcomes

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103714

S.R. Javed, S. Mathur, K. DeSouza, A. Konstantis, D. Ottaviani, F. Raja, R. Roylance, T. Walsh, E. Papadimitraki

引用次数: 0

Single centre experience of neo-adjuvant chemotherapy for HER2 positive early breast cancer and impact of chemotherapy regimen on pathological complete response (pCR)

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103707

M. Joseph, A. Guppy, S. Sutherland, C. Westbury, W. Ng, D. Miles

引用次数: 0

Alpelisib in advanced breast cancer – a real world report of toxicity and efficacy, a multi-centre analysis

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103708

L. Morrison , D. Banon , I. Gill , N. Cunningham , A. Dua , A. Ballesteros , P.L. Marti , P. Galera , M. Alvarez-Maldonado , A. Iglesias , E. Carrillo , N.C. Turner , M. Parton , S. Johnston , E. Kipps , A.F.C. Okines

引用次数: 0

A retrospective audit of adherence to the IMPORT-HIGH recommendations on clip placement to facilitate breast boost radiotherapy

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103710

L. Alizadeh, A. Mitchell, C. Kane, E. Halliday, S. Needleman

引用次数: 0

Under-representation for Female Pelvis Cancers in Commercial Auto-segmentation Solutions and Open-source Imaging Datasets 商业自动分割解决方案和开源成像数据集中女性骨盆癌的代表性不足。

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.10.003

M. Thor , V. Williams , C. Hajj , L. Cervino , H. Veeraraghavan , S. Elguindi , N. Tyagi , A. Shukla-Dave , J.M. Moran

{"title":"Under-representation for Female Pelvis Cancers in Commercial Auto-segmentation Solutions and Open-source Imaging Datasets","authors":"M. Thor , V. Williams , C. Hajj , L. Cervino , H. Veeraraghavan , S. Elguindi , N. Tyagi , A. Shukla-Dave , J.M. Moran","doi":"10.1016/j.clon.2024.10.003","DOIUrl":"10.1016/j.clon.2024.10.003","url":null,"abstract":"<div><h3>Aim</h3><div>Artificial intelligence (AI) based auto-segmentation aids radiation therapy (RT) workflows and is being adopted in clinical environments facilitated by the increased availability of commercial solutions for organs at risk (OARs). In addition, open-source imaging datasets support training for new auto-segmentation algorithms. Here, we studied if the female and male anatomies are equally represented among these solutions.</div></div><div><h3>Materials and Methods</h3><div>Inquiries were sent to eight vendors regarding their clinically available OAR auto-segmentation solutions for each gender. The Cancer Imaging Archive (TCIA) was also screened for publicly available imaging datasets specific to the female and the male anatomy.</div></div><div><h3>Results</h3><div>All vendors provided AI based auto-segmentation solutions for the male pelvis and female breasts, while 5/8 vendors provided solutions for the female pelvis. The female breast and the female pelvis solutions were released at a median of 0.6 years and 2.3 years, respectively, after the release of the male pelvis solutions. Among 27 TCIA datasets identified, 15 involved the female anatomy (breast: 10; pelvis: 5) and 12 involved the male pelvis but no female-specific dataset included OAR segmentations, while three male pelvis datasets included OARs (ejaculatory duct, neurovascular bundle, penile bulb and verumontanum).</div></div><div><h3>Conclusion</h3><div>Commercial AI auto-segmentation solutions and open-source imaging datasets include considerably more solutions and OAR segmentations for male cancer over female cancer sites. This gender disparity is likely to propagate throughout the RT pipeline.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"38 ","pages":"Article 103651"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is exercise an important consideration in metastatic breast cancer? 运动是转移性乳腺癌患者的重要考虑因素吗？

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103718

A. Kuciejewska, C. Lai, M. Kitson, C. McDaid, M. Chody, N. Chopra

引用次数: 0

A Systematic Review of Deep Inspiration Breath Hold and Free Breathing in Proton Beam Therapy Plans for Breast Cancer Radiotherapy

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2025.103782

F. Wilson , P. Gupta , H. Halvorsen , C. Anandadas , D. Lines , M. Aznar

{"title":"A Systematic Review of Deep Inspiration Breath Hold and Free Breathing in Proton Beam Therapy Plans for Breast Cancer Radiotherapy","authors":"F. Wilson , P. Gupta , H. Halvorsen , C. Anandadas , D. Lines , M. Aznar","doi":"10.1016/j.clon.2025.103782","DOIUrl":"10.1016/j.clon.2025.103782","url":null,"abstract":"<div><h3>Aims</h3><div>To conduct a systematic review of breast cancer radiotherapy studies reporting a comparison of proton beam therapy (PBT) in deep inspiration breath hold (DIBH) and in free breathing (FB).</div></div><div><h3>Methods and materials</h3><div>Studies comparing DIBH and FB proton beam therapy plans, in the same patient, published between 2015 and 2023 were included. Doses to organs at risk were compared between DIBH and FB plans.</div></div><div><h3>Results</h3><div>Nine papers were identified for inclusion, reporting on 97 patients in total. All plans were for left-sided treatment. Average weighted mean heart dose was 0.31 Gy for DIBH and 0.48 Gy for FB. Average weighted mean left lung dose was 5.27 Gy for DIBH and 4.80 Gy for FB. Average weighted mean near maximum/maximum left anterior descending artery dose was 6.49 Gy for DIBH and 8.74 Gy for FB.</div></div><div><h3>Conclusion</h3><div>Based on the current literature, it does not appear that DIBH offers a marked dosimetric benefit to most breast cancer patients treated with PBT. However, the benefits of combining PBT and DIBH for individual breast RT patients cannot be excluded.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"40 ","pages":"Article 103782"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143474199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0